ClinicalTrials.gg
RecruitingNCT07681791Updated Aug 5, 2026

Sun Safe Together: A Digital Skin Cancer Prevention Intervention for Adolescents and Their Parents

An interventional study of Teen MMS and Parent Facebook in Skin Cancer Prevention, sponsored by Rutgers, The State University of New Jersey. Recruiting at 1 site in United States. Open to participants aged 13 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Not applicable
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Skin Neoplasms with a site in United States — 64 open to participants now, 98 under way, 7 of them phase 3. Skin Neoplasms · United States.

Planned enrollment
89th of 290
104 · median 44
Started
2026
with 16 others
No phase
97 of 381
18 open now
Primary completion
2027-12
later than 58 of 96 live
Registered
372nd of 381
by date

Among the 381 studies in Skin Neoplasms with a site in United States, this one is the 89th largest by planned enrollment of the 290 interventional ones that give a count, is one of 17 that started in 2026, is one of 97 with no phase, reaches primary completion later than 58 of the 96 other live ones, and was the 372nd registered.

Skin Neoplasms

606 studies on the registry are indexed under Skin Neoplasms; 127 are open to participants now.

Browse Skin Neoplasms studies →

Open to participants now

64 of the 381 studies in Skin Neoplasms with a site in United States are open now. Recruiting first, the newest first:

58 more — sign in →

All 64 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 105 Skin Neoplasms studies recruiting now, 85 (81%) set no upper age limit and 9 (9%) stop at 75 or younger; 15 take children under 18; 25 take healthy volunteers.

This study: 13 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Skin Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this pilot clinical trial is to learn if a digital intervention to improve sun safety, Sun Safe Together (SST), is feasible and acceptable to teenagers and their parents.

Read the detailed description

Melanoma is a leading cause of invasive cancer in teens and young adults aged 15-39. Most skin cancers are preventable with skin protection such as minimizing UVR exposure and wearing protective clothing and sunscreen. However, teens have low levels of sun protection. Thus, interventions targeting skin cancer risk reduction among teens are needed. The proposed Sun Safe Together (SST) intervention is a 12-week program consisting of sun safety and general health messages sent via multimedia messaging service (MMS) to teens and via a private Facebook group for parents.

This pilot trial is a single arm test of SST to determine:

  1. feasibility of enrolling parent-teen dyads
  2. engagement with/acceptability of the intervention via message views and acceptability ratings
  3. outcome data collection feasibility (i.e., daily diary, UVR exposure measured by UVR dosimeter)
  4. retention rates for teens and parents at 3 and 6 months
03

Conditions studied

  • Skin Cancer Prevention

Browse trials for

Keywords

  • Sun Safety
  • Teens
  • Messages
  • Teen health
  • Parents
  • Education
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Parents and teens are participating as dyads, meaning both the parent and the teen need to be deemed eligible based on the criteria below to be able to participate.

Teens

  • Must be ages 13-17 years
  • Live with study parent equal to or greater than half time in US
  • Have experienced sunburn or indoor tanned in the last year or have a suboptimal sun protection score
  • Have no personal history of melanoma or severe medical condition that prevents participation
  • Have access to smartphone
  • Speak and read English

Parents/Guardians

  • Must be age 18 or older
  • Live with a teen equal to or greater than half time in US
  • Have a teen who had experienced sunburn or indoor tanned in the last year or have a suboptimal sun protection score
  • Have no personal history of melanoma or severe medical condition that prevents participation
  • Have internet at home, a Facebook account, and be willing to use Facebook daily
  • Have access to smartphone
  • Speak and read English
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Teen MMS & Parent Facebook Intervention

    Behavioral: Teen MMS · Behavioral: Parent Facebook

Interventions

  • BehavioralTeen MMS

    Teens will receive MMS messages regarding sun safety behaviors and other general health issues for 12 weeks.

  • BehavioralParent Facebook

    Parents of teenagers join a private Facebook group where membership, activities, and content are only viewable by invited members. Content related to teen sun safety and general health will be posted for 12 weeks. Research staff will moderate the group.

06

What researchers measure

Primary outcomes

  1. Feasibility of recruitment

    Feasibility of recruitment will be assessed by the proportion of eligible parent-teen dyads that enroll in the study

    Time frame: Baseline

  2. Acceptability of MMS intervention

    Items were adapted from the Acceptability of Intervention and Feasibility of Intervention Measures to obtain participant feedback about the acceptability, feasibility, ease of use, and impact of the intervention. Individual items are rated on a 5-point likert scale from (1) Completely Disagree to (5) Completely Agree. Higher scores indicated greater acceptability.

    Time frame: Immediately after the intervention

  3. Engagement with MMS intervention

    Proportion of messages viewed will be calculated to describe engagement.

    Time frame: 3-months

  4. Feasibility of Outcome Data Collection - 7-Day Diaries

    Proportion of teens who complete 7-day diaries will be calculated.

    Time frame: Baseline, 3-months, 6-months

  5. Feasibility of Outcome Data Collection - UVR Dosimeter

    Proportion of teens who return UVR dosimeter with usable data will be calculated.

    Time frame: Baseline, 6 months

  6. Retention

    Proportion of enrolled teens who complete surveys at 3- and 6-months will be calculated.

    Time frame: 3-months, 6-months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified study data and associated documentation will be made available to the research community through the Data Sharing for Demographic Research (DSDR) data repository hosted at the Inter-university Consortium for Political and Social Research (ICPSR).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available by the time of associated publication or the end of grant funding (whichever is later). The duration of preservation and sharing of the data will be indefinite.

Access criteria: De-identified human subject data will be made available in the Inter-university Consortium for Political and Social Research (ICPSR) data repository, which restricts access to the data to qualified investigators with an appropriate research question who complete a data use agreement and provide a data security plan.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2027, 16 months later.

Of 94 non-industry interventional studies with no phase under Skin Neoplasms, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 49. This study's planned 16 months is below that.

Counting every sponsor, half of 116 studies reached it within 27 months; a quarter within 10 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 2, 2026
StartEst.
Aug 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07681791
Responsible party
Dr. Carolyn Heckman, Ph.D (Professor, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Jul 2, 2026
Start date
Aug 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

Carolyn Heckman, PhD
principal investigator · Rutgers, The State University of New Jersey
Katie A Devine, PhD
principal investigator · Rutgers, The State University of New Jersey

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion